Skip to main content

Table 3 Adverse events reported during the study

From: Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab

Characteristics Frequency
Significant loss in VA (progressive retinal scarring) 2
Epithelial defect secondary to intravitreal injection 1
Subretinal haemorrhage 1
Subconjunctival haemorrhage 1
Retinal tear requiring retinopexy 1
Atrial fibrillation 1
Stroke 1
VZV infection/Shingles 2
Metastatic cancer diagnosed during treatment 1